User login
Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.
Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).
Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.
Disclosures: This study did not receive any funding. The authors declared no conflict of interests.
Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source
Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.
Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).
Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.
Disclosures: This study did not receive any funding. The authors declared no conflict of interests.
Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source
Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.
Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).
Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.
Disclosures: This study did not receive any funding. The authors declared no conflict of interests.
Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source